PT Kalbe Farma Tbk (FRA:LCLA) Moat Score: 6/10 (As of Jul. 02, 2026)


FRA:LCLA PT Kalbe Farma Tbk FRA:LCLA
77 GF Score
Price €0.03
GF Value €0.07
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is PT Kalbe Farma Tbk Moat Score?

PT Kalbe Farma Tbk FRA:LCLA 77 Moat Score is 6 as of Jul. 02, 2026. GuruFocus rates FRA:LCLA with a GF Score™ of 77/100 and a GF Value™ of €0.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,032 Drug Manufacturers companies, PT Kalbe Farma Tbk ranks better than 97.09% on this metric.

PT Kalbe Farma Tbk has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

PT Kalbe Farma Tbk has Narrow Moat: PT Kalbe Farma has a strong narrow moat due to its leading position in Indonesia's pharmaceutical market, supported by brand strength and a robust distribution network. It benefits from economies of scale and consistent R&D, but faces competition and lacks significant global market influence.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes PT Kalbe Farma Tbk might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

PT Kalbe Farma Tbk  (FRA:LCLA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

PT Kalbe Farma Tbk Moat Score Related Terms

FRA:LCLA vs LLY, JNJ, ABBV: Moat Score Comparison

For the Drug Manufacturers - General subindustry, PT Kalbe Farma Tbk's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PT Kalbe Farma Tbk Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PT Kalbe Farma Tbk's Moat Score distribution charts can be found below:

* The bar in red indicates where PT Kalbe Farma Tbk's Moat Score falls into.


FRA:LCLA
77GF Score
PT Kalbe Farma Tbk FRA:LCLA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
PT Kalbe Farma Tbk (FRA:LCLA) has a Moat Score of 6 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, PT Kalbe Farma Tbk ranks #30 out of 1032 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is PT Kalbe Farma Tbk's Moat Score too high?
PT Kalbe Farma Tbk's current Moat Score is 6. Based on the distribution chart, PT Kalbe Farma Tbk ranks #30 out of 1032 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PT Kalbe Farma Tbk has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kalbe Farma Tbk's Moat Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, PT Kalbe Farma Tbk ranks #30 out of 1032 companies for Moat Score. This places PT Kalbe Farma Tbk in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. PT Kalbe Farma Tbk's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kalbe Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk (FRA:LCLA) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.07, compared to a current price of €0.03 — trading 57.1% below its estimated fair value. The current Moat Score is 6. PT Kalbe Farma Tbk's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For PT Kalbe Farma Tbk (FRA:LCLA), the current Moat Score is 6 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Kalbe Farma Tbk (FRA:LCLA) Overvalued in 2026?

Based on GuruFocus' analysis, PT Kalbe Farma Tbk stock appears to be undervalued. The current stock price of €0.03 is trading 57.1% below its estimated GF Value™ of €0.07. GuruFocus considers PT Kalbe Farma Tbk to be Significantly Undervalued.

Key valuation signals for FRA:LCLA:

  • Moat Score: 6
  • GF Value™: €0.07 vs. price of €0.03 (57.1% below fair value)
  • GF Score™: 77/100 with 2 warning signs

No single metric tells the full story. See the FRA:LCLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PT Kalbe Farma Tbk Business Description

Address Jalan Let. Jend. Suprapto Kav. 4, Gedung KALBE, Cempaka Putih, P.O. Box 3105, Jakarta, IDN, 10510
PT Kalbe Farma Tbk is engaged in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's revenue is derived from the distribution and logistics segments. Its Product and Services are Prescription /Ethicals, Consumer Health, Nutritionals, Distribution & Logistics, Health Services, Medical Devices, and Others.
77GF Score

Get the complete analysis for FRA:LCLA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price
€0.07
GF Value